Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Seagen Inc. v. Daiichi Sankyo Co., Ltd.
Case Number:
2:20-cv-00337
Court:
Nature of Suit:
Judge:
Firms
- Covington & Burling
- Dacus Law Firm
- Gillam Smith
- Miller Fair
- Morrison & Foerster
- MT2 Law Group
- Paul Hastings
- Williams & Connolly
- Willkie Farr
- Wilson Robertson & VanDeventer
Companies
Sectors & Industries:
-
October 20, 2020
Daiichi Faces Patent Suit Over New Breast Cancer Drug
Daiichi Sankyo is facing claims in Texas federal court that its recently approved breast cancer treatment drug, which has allegedly earned the Japanese pharmaceutical giant $70 million in sales, infringes a U.S. biotechnology company's patent.
- ← Previous
- 1
- 2
- Next →